ACB
Price
$4.96
Change
-$0.08 (-1.59%)
Updated
May 15, 04:59 PM (EDT)
Capitalization
238.86M
35 days until earnings call
KMDA
Price
$6.88
Change
-$0.17 (-2.41%)
Updated
May 15, 04:59 PM (EDT)
Capitalization
306.49M
90 days until earnings call
Ad is loading...

ACB vs KMDA

Header iconACB vs KMDA Comparison
Open Charts ACB vs KMDABanner chart's image
Aurora Cannabis
Price$4.96
Change-$0.08 (-1.59%)
Volume$15.55K
Capitalization238.86M
Kamada
Price$6.88
Change-$0.17 (-2.41%)
Volume$200
Capitalization306.49M
ACB vs KMDA Comparison Chart
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. KMDA commentary
May 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a StrongBuy and KMDA is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 16, 2025
Stock price -- (ACB: $5.04 vs. KMDA: $7.05)
Brand notoriety: ACB: Notable vs. KMDA: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ACB: 60% vs. KMDA: 321%
Market capitalization -- ACB: $238.86M vs. KMDA: $306.49M
ACB [@Pharmaceuticals: Other] is valued at $238.86M. KMDA’s [@Pharmaceuticals: Other] market capitalization is $306.49M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileKMDA’s FA Score has 1 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • KMDA’s FA Score: 1 green, 4 red.
According to our system of comparison, KMDA is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 6 TA indicator(s) are bullish while KMDA’s TA Score has 7 bullish TA indicator(s).

  • ACB’s TA Score: 6 bullish, 4 bearish.
  • KMDA’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, KMDA is a better buy in the short-term than ACB.

Price Growth

ACB (@Pharmaceuticals: Other) experienced а +9.80% price change this week, while KMDA (@Pharmaceuticals: Other) price change was +3.52% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.89%. For the same industry, the average monthly price growth was +10.81%, and the average quarterly price growth was +26.24%.

Reported Earning Dates

ACB is expected to report earnings on Aug 07, 2025.

KMDA is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.89% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KMDA($306M) has a higher market cap than ACB($239M). KMDA (19.081) and ACB (18.588) have similar YTD gains . KMDA has higher annual earnings (EBITDA): 22.4M vs. ACB (-1.64B). ACB has more cash in the bank: 149M vs. KMDA (55.6M). KMDA has less debt than ACB: KMDA (8.82M) vs ACB (103M). ACB has higher revenues than KMDA: ACB (212M) vs KMDA (143M).
ACBKMDAACB / KMDA
Capitalization239M306M78%
EBITDA-1.64B22.4M-7,308%
Gain YTD18.58819.08197%
P/E RatioN/A37.43-
Revenue212M143M148%
Total Cash149M55.6M268%
Total Debt103M8.82M1,168%
FUNDAMENTALS RATINGS
ACB vs KMDA: Fundamental Ratings
ACB
KMDA
OUTLOOK RATING
1..100
2520
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
9182
PRICE GROWTH RATING
1..100
5145
P/E GROWTH RATING
1..100
6232
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACB's Valuation (58) in the Pharmaceuticals Other industry is in the same range as KMDA (74) in the Biotechnology industry. This means that ACB’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's Profit vs Risk Rating (93) in the Biotechnology industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that KMDA’s stock grew similarly to ACB’s over the last 12 months.

KMDA's SMR Rating (82) in the Biotechnology industry is in the same range as ACB (91) in the Pharmaceuticals Other industry. This means that KMDA’s stock grew similarly to ACB’s over the last 12 months.

KMDA's Price Growth Rating (45) in the Biotechnology industry is in the same range as ACB (51) in the Pharmaceuticals Other industry. This means that KMDA’s stock grew similarly to ACB’s over the last 12 months.

KMDA's P/E Growth Rating (32) in the Biotechnology industry is in the same range as ACB (62) in the Pharmaceuticals Other industry. This means that KMDA’s stock grew similarly to ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBKMDA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 4 days ago
63%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 2 days ago
66%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 4 days ago
67%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
70%
View a ticker or compare two or three
Ad is loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA347.6813.61
+4.07%
Tesla
GME28.730.34
+1.20%
GameStop Corp
SPY587.590.75
+0.13%
SPDR® S&P 500® ETF
AAPL212.33-0.60
-0.28%
Apple
BTC.X103539.414000-630.398440
-0.61%
Bitcoin cryptocurrency

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been closely correlated with CGC. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
-2.33%
CGC - ACB
81%
Closely correlated
-2.76%
OGI - ACB
61%
Loosely correlated
-1.61%
CRON - ACB
58%
Loosely correlated
+0.98%
TLRY - ACB
58%
Loosely correlated
-2.00%
SCYX - ACB
33%
Poorly correlated
-1.57%
More

KMDA and

Correlation & Price change

A.I.dvisor tells us that KMDA and OGI have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and OGI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
+2.32%
OGI - KMDA
26%
Poorly correlated
-1.61%
RDY - KMDA
26%
Poorly correlated
+0.28%
SCYX - KMDA
23%
Poorly correlated
-1.57%
INCR - KMDA
23%
Poorly correlated
-0.65%
ACB - KMDA
23%
Poorly correlated
-2.33%
More